Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services enabling biopharma companies to bring new medicines to market, has added Cheryl Murphy as senior vice president, Clinical Development to its executive team.
In her global role, Murphy oversees multiple operational groups, including regulatory affairs, feasibility/patient & site advocacy, project management, clinical operations, clinical project central, and functional service provider divisions. Cheryl is based in Synteract’s RTP, North Carolina office and reports directly to CEO Steve Powell.
“I am very pleased to welcome Cheryl, a visionary and accomplished leader in clinical development, to our impressive Synteract executive team. Her experience will help advance our operational delivery in our next stage of growth and will support the needs of our global customers,” said Steve Powell, CEO of Synteract. “As an innovative CRO supporting biopharma companies in some of the most progressive therapeutic areas, both the Synteract team and our customers will greatly benefit from Cheryl’s expertise and deep leadership capabilities.”
As senior vice president of Clinical Development, Cheryl Murphy draws on over 20 years of CRO, pharmaceutical, and consulting industry experience. She comes to Synteract from an 11-year tenure in customer management, functional services provision and operations roles at IQVIA, where she most recently served as chief of staff for the president of Clinical Operations. She also previously worked in project management and information technology roles at Merck KGaA/EMD and was a consultant, providing information technology, business process re-engineering, and change management expertise to Fortune 100 clients at Accenture.
About Synteract
With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in oncology, dermatology and neuro degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005213/en/
Source: Synteract
View this news release online at:
http://www.businesswire.com/news/home/20180719005213/en
